Metformin-associated lactic acidosis: Moving towards a new paradigm?

Diabetes, Obesity and Metabolism

Volumn 19, Issue 11, 2017, Pages 1499-1501

  Bicsak, Thomas A ^a   Walsh, Brandon ^a   Fineman, Mark ^a  

^a Elcelyx Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; METFORMIN; ANTIDIABETIC AGENT;

ACUTE KIDNEY FAILURE; AEROBIC METABOLISM; DRUG ACCUMULATION; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; EDITORIAL; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; PH; PRACTICE GUIDELINE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACIDOSIS, LACTIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 85020436997     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12994     Document Type: Editorial

References (15)

1. Lalau J-D, Kajbaf F, Protti A, Christensen MM, Broe ME, Wiernsperger N. Metformin-associated lactic acidosis (MALA): moving towards a new paradigm. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.12974.
2. Connelly PJ, Lonergan M, Soto-Pedre E, Donnelly L, Zhou K, Pearson ER. Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: a GoDarts study. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.12978.
3. Neal A, Rountree AM, Philips CW, et al. Quantification of low-level drug effects using real-time, in vitro measurement of oxygen consumption rate. Toxicol Sci. 2015;148(2):594-602.
4. Ozeki T, Kawato R, Watanabe M, et al. A fatal case of metformin-associated lactic acidosis. Intern Med. 2016;55(7):775-778.
5. Zibar L, Zibar K. Hemodialysis-refractory metformin-associated lactate acidosis with hypoglycemia, hypothermia, and bradycardia in a diabetic patient with belated diagnosis and chronic kidney disease. Int J Clin Pharmacol Ther. 2017;55(4):348-351.
6. Boucaud-Maitre D, Ropers J, Porokhov B, et al. Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. Diabet Med. 2016;33(11):1536-1543.
7. Chowdhury TA, Srirathan D, Abraham G, et al. Could metformin be used in patients with diabetes and advanced chronic kidney disease? Diabetes Obes Metab. 2017;19(2):156-161.
8. Kumar SS, Graham GG, Smith FC, et al. Could metformin be used in patients with advanced chronic kidney disease? Diabetes Obes Metab. 2017;19(2):302-303.
9. Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS ONE. 2014;9(7):e100778.
10. Duca FA, Cote CD, Rasmussen BA, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med. 2015;21(5):506-511.
11. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-266.
12. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation. results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198-205.
13. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426-435.
14. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98.
15. Jones GC, Sainsbury CAR. Comment on ‘A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure’. Diabet Med. 2015;32(2):287.